ProKidney Corp.

Healthcare · Biotechnology · United States

Last price 1.295 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 391.51M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, a...